Neuroprotective treatment for Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 3, Issue 6, 2003, Pages 797-804

  Aminoff, Michael J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coenzyme Q10; Creatine; Glial derived neurottrophic factor; Glutamine oxidase inhibitors; Neuroprotection; Parkinson's disease; Rasagiline; Selegiline; Trial design

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CAFFEINE; CARNITINE; CEP 1347; CREATINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; GANGLIOSIDE GM1; GINKGO BILOBA EXTRACT; LAZABEMIDE; MINOCYCLINE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINAMIDE; NICOTINE; PETHIDINE; PRAMIPEXOLE; REMACEMIDE; RILUZOLE; THIOCTIC ACID;

ARTICLE; CYTOTOXICITY; DRUG MECHANISM; GINKGO BILOBA; HUMAN; NEUROPROTECTION; PARKINSON DISEASE; PHYSICIAN; PUBLICATION; TIME; VALIDATION PROCESS;

EID: 0344014160     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.3.6.797     Document Type: Article

References (49)

1. Reich SG, Lederman MB, Griswold ME. Errors and delays in diagnosing Parkinson's disease. Ann. Neurol. 52, S84 (2002).
2. Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61, 1191-1206 (1993).
3. McCormack AL, Thiruchelvam M, Manning-Bog AB et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 10, 119-127 (2002).
4. Menegon A, Board PG, Blackburn AC et al. Parkinson's disease, pesticides and glutathione transferase polymorphisms. Lancet 352, 1344-1346 (1998).
5. Butterfield PG, Valanis BG, Spencer PS et al. Environmental antecedents of young-onset Parkinson's disease. Neurology 43, 1150-1158 (1993).
6. Gorell JM, Johnson CC, Rybicki BA et al. The risk of Parkinson's disease with exposure to pesticides, farming, well water and rural living. Neurology 50, 1346-1350 (1998).
7. Engel LS, Checkoway H, Keifer MC et al. Parkinsonism and occupational exposure to pesticides. Occup. Environ. Med. 58, 582-589 (2001).
8. Betarbet R, Sherer TB, MacKenzie G. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neurosci. 3, 1301-1306 (2000).
9. Hicks AA, Perursson H, Jonsson T. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann. Neurol. 52, 549-555 (2002).
10. Maruyama W, Akao Y, Carrillo MC et al. Neuroprotection by propargylamines in Parkinson's disease. Suppression of apoptosis and induction of prosurvival genes. Neurotox. Teratol. 24, 675-682 (2002).
11. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson's disease: the TEMPO study. Arch. Neurol. 59, 1937-1943 (2002).
12. Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann. Neurol. 40, 99-107 (1996).
13. Schapira AH, Cooper JM, Dexter D et al. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54, 823-827 (1990).
14. 10 in early Parkinson's disease. Arch. Neurol. 59, 1541-1550 (2002).
15. Rosenberg RN. Mitochondrial therapy for Parkinson's disease. Arch. Neurol. 59, 1523 (2002).
16. Beal MF. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann. Neurol. 53(Suppl. 3), S39-S48 (2003). Review of experimental and clinical evidence that impaired mitochondrial function, oxidative damage, and inflammation contribute to the pathogenesis of Parkinson's disease.
17. Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat. Disord. 8, 271-276 (2002).
18. Rascol O, Olanow CW, Brooks D et al. A 2-year, multicenter, placebo-controlled, double-blind, parallel group study of the effect of riluzole on Parkinson's disease progression. Mov. Disord. 17(Suppl. 5), S39 (2002).
19. Beal MF. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann. Neurol. 44, S110-S114 (1998).
20. Du Y, Ma Z, Lin S et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl Acad. Sci. 98, 14669-14674 (2001).
21. Bruet N, Windels F, Bertrand A et al. High frequency stimulation of the subthalamic nucleus increases the extracellular contents of striatal dopamine in normal and partially dopaminergic denervated rats. Neuropathol. Exp. Neurol. 60, 15-24 (2001).
22. Luo J, Kaplitt MG, Fitzsimons HL et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298, 425-429 (2002).
23. Kreiss DS, Mastropietro CW, Rawji SS, Walters JR. The response of subthalamic nucleus to dopamine receptor stimulation in a rodent model of Parkinson's disease. J. Neurosci. 17, 6807-6819 (1997).
24. Parkinson Study Group. A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD. Neurology 54, 1583-1588 (2000).
25. McGeer PL, Yasojima K, McGeer EG. Inflammation in Parkinson's disease. Adv. Neurol. 86, 83-89 (2001).
26. Langston JW, Forno LS, Tetrud J et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46, 598-605 (1999).
27. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M et al. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp. Neurol. 156, 50-61 (1999).
28. Wu DC, Jackson-Lewis V, Vila M et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neurosci. 22, 1763-1771 (2002). Experimental study demonstrating that minocycline, which inhibits microglial activation, reduces nigrostriatal dopaminergic cell loss produced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
29. Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39, 167-174 (2001).
30. Liu B, Gao HM, Wang JY et al. Role of nitric oxide in inflammation-mediated neurodegeneration. Ann. NY Acad. Sci. 962, 318-331 (2002).
31. Fahn S. Parkinson's disease, the effect of levodopa and the ELLDOPA trial. Arch. Neurol. 56, 529-535 (1999).
32. Agid Y. Levodopa: is toxicity a myth? Neurology 50, 858-863 (1998).
33. Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/ cortical astrocyte cocoltures. J. Neurochem. 69, 1398-1408 (1997).
34. Murer MG, Dziewczapolski G, Menalled LB et al. Chronic levodopa is not toxic for remaining dopamine neurons but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. 43, 561-575 (1998).
35. Kitamura Y, Kosaka T, Kakimura JI et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 54, 1046-1054 (1998).
36. Linazasoro GL. Neuroprotection in Parkinson's disease: love story or mission impossible? Expert Rev. Neurotherapeutics 2, 403-416 (2002).
37. Morrish, P. Is it time to abandon functional imaging in the study of neuroprotection? Mov. Disord. 17, 229-232 (2002).
38. Guttman M, Stewart D, Hussey D et al. Influence of L-DOPA and pramipexole on striatal dopamine transporter in early PD. Neurology 56, 1559-1564 (2001).
39. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson's disease progression. JAMA 287, 1653-1661 (2002).
40. Grondin R, Zhang Z, Yi A et al. Chronic controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125, 2191-2201 (2002). Glial-derived neurotrophic factor (GDNF) infused into the striatum and lateral ventricle of a monkey-model of Parkinson's disease led to functional improvement accompanied by upregulation and regeneration of nigral dopaminergic neurons.
41. Brundin P. GDNF treatment in Parkinson's disease: time for controlled clinical trials? Brain 125, 2149-2151 (2002).
42. Shingo T, Date I, Yoshida H, Ohmoto T. Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF-producing cells in a rat model of Parkinson's disease. J. Neurosci. Res. 69, 946-954 (2002).
43. Kordower JH, Palfi S, Chen EY et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 46, 419-424 (1999).
44. Gill SS, Patel NK, Hotton GR et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson's disease. Nature Med. 9, 589-595 (2003). GDNF delivered into the putamen of five patients was without serious side-effects and led to symptomatic benefit.
45. Emborg ME, Shin P, Roitberg B et al. Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys. Exp. Neurol. 168, 171-182 (2001).
46. Eberling JL Pivirotto P, Bringas J et al. The immunophilin ligand GOI-1046 does not have neuroregenerative effects in MPTP-treated monkeys. Exp. Neurol. 178, 236-242 (2002).
47. Saporito MS, Brown EM, Miller MS, Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol. Exp. Ther. 288, 421-427 (1999).
48. Kieburtz K. Designing neuroprotection trials in Parkinson's disease. Ann. Neurol. 53(Suppl. 3), S100-S109 (2003). Reviews approaches to the design of clinical trials to assess neuroprotective treatments.
49. Stocchi F, Olanow CW. Neuroprotection in Parkinson's disease: clinical trials. Ann. Neurol. 53(Suppl. 3), S87-S99 (2003). Reviews some of the earlier clinical trials of possible protective agents, with discussion of some of the difficulties in designing and interpreting such trials.